Strategic partnership pull Recent news shows Amgen ended its partnership with TScan, indicating potential opportunity for a new or expanded collaboration with other large biotech or pharma companies seeking entry into TCR-T therapies or complementary platforms.

Manufacturing collaboration TScan is actively pursuing automated clinical manufacturing discussions with Cellares for TCR-T therapies in AML, signaling an openness to co-develop scalable production solutions which can be pitched to biopharma partners seeking manufacturing efficiency.

Clinical pipeline momentum As a clinical-stage TCR-T company with ongoing presentations at major conferences, there is value in approaching clinical-stage investors or pharma companies looking to license or co-develop next-generation TCR-T assets across oncology and immune-related indications.

Financial footprint With substantial funding (~$410M) and revenue in the lower tens of millions, there is a compelling story for strategic customers or partners to invest in joint development, while offering potential co-funding arrangements to de-risk early-stage collaborations.

Platform capabilities TScan’s rapid TCR discovery platform and versatility across cancer, autoimmune, and infectious disease applications suggest cross-therapeutic collaboration opportunities, including licensing of discovery tech, access to targets, or joint development in non-oncology franchises.